- Letter to the Editor
- Open Access
Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma
Journal of Ophthalmic Inflammation and Infection volume 9, Article number: 11 (2019)
Vitreoretinal lymphoma as the presenting diagnosis in association with a systemic lymphoma without central nervous system involvement is exceedingly rare, and the classification of this condition is not well-established. Here, we describe a patient with intermittent blurry vision in the left eye for 2 years in the setting of a recent incidental diagnosis of diffuse large B cell lymphoma from an axillary lymph node biopsy. The diagnosis of panuveitis with an extensive exudative retinal detachment was made. The patient was treated with pars plana vitrectomy as well as systemic chemotherapy, intrathecal methotrexate, intravitreal methotrexate, and intravitreal rituximab with good post-operative outcomes.
Vitreoretinal lymphoma has classically been identified as a primary intraocular malignancy associated with primary central nervous system (CNS) lymphoma [1, 2]. When systemic lymphoma results in intraocular manifestations, the involvement is typically choroidal [1, 2]. However, recent reports of vitreoretinal lymphoma in the setting of systemic lymphoma have provided insight into the clinical presentation of non-primary vitreoretinal lymphoma (VRL) [3,4,5,6]. Rapid diagnosis, work-up, and treatment of secondary VRL (SVRL) are paramount as it can commonly masquerade as primary vitreoretinal lymphoma (PVRL) as well as retinitis, uveitis, and vasculitis [4, 6]. Here, we describe a case with a primary presentation of vitreous hemorrhage and underlying exudative retinal detachment secondary to an undiagnosed secondary vitreoretinal diffuse large B cell lymphoma (DLBCL) associated with a systemic DLBCL.
A 54-year-old Korean male was referred to the uveitis service with the diagnosis of intermittent vitreous hemorrhage of unknown etiology in the left eye for 2 years. A week prior to presentation, the patient sustained trauma to his left arm resulting in a deep vein thrombosis. A thrombolectomy resulted in an incidental diagnosis of diffuse large B cell lymphoma, an activated B cell (ABC) subtype, from axillary lymph nodes. A review of systems revealed no history of severe infections, immunosuppression, nor intravenous drug use.
On presentation, the visual acuity was 20/20 in the right eye and 200E at 1 ft in the left eye. Examination of the left eye was notable for diffuse keratic precipitates and 1+ anterior chamber cell, as well as 4+ vitreous cell with intraretinal hemorrhage (Fig. 1a, b). Fundus autofluorescence, fluorescein angiography (FA), indocyanine green (ICG, Fig. 1e–h), and optical coherence tomography (OCT, Fig. 2a, b) of the left eye were limited due to the vitritis. B-scan ultrasound noted a serous retinal detachment without any retinal breaks (Fig. 2c). All imaging studies of the right eye were normal. Infectious and inflammatory work-up was negative, including normal CBC, Quantiferon, FTA-ABS, angiotensin-converting enzyme, and Toxoplasmosis IgG and IgM antibodies.
A diagnostic and therapeutic pars plana vitrectomy was performed. An exudative retinal detachment with significant subretinal yellow-white deposits, sclerotic vessels, and intraretinal hemorrhages was noted (Fig. 3). No retinal breaks were identified, and no drainage of subretinal fluid was performed. Vitreous samples as well as the cassette were sent for microbiology, cytology, flow cytometry, pathology, and PCR.
Post-operatively, the patient was placed on topical steroids as well as oral valacyclovir. However, all vitreous microbiological studies were negative. Follow-up FA can be seen in Fig. 4. Pathology specimens demonstrated atypical CD20-positive lymphocytes consistent with large B cell lymphoma (Fig. 5). Histology and flow cytometry demonstrated a monoclonal B cell lymphoproliferative process, positive for CD19 and CD20 overexpression. Additional studies can be seen in Table 1 below. On further systemic work-up, orbital ultrasound, MRI of the head, orbit, face, and neck as well as whole body PET scan and cerebrospinal fluid analysis were normal.
The patient underwent intrathecal methotrexate and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with simultaneous intravitreal methotrexate (0.4 mg/0.1 ml) and rituximab (1 mg/0.1 ml). After five injections of methotrexate and four injections of rituximab, there was a complete resolution of the exudative retinal detachment as well as resolution of subretinal infiltrate and hemorrhage as seen on fundus photos and OCT (Fig. 6) and improvement in best corrected visual acuity to 20/200.
Our case represents a rare presentation of intraocular VRL associated with systemic lymphoma. In the current report, ocular symptoms preceded axillary lymph node diagnosis of DLBCL, demonstrating a rare case in the literature where intraocular manifestations were the first indications of systemic disease. It is unclear whether it is best to term this VRL as primary or secondary, because although the diagnosis of systemic lymphoma preceded the diagnosis of VRL, the ocular symptoms preceded systemic symptoms and diagnosis by 2 years. In general, intraocular lymphomas are rare. The vast majority of vitreoretinal lymphomas are primary (PVRL) and are categorized as a subset of primary CNS lymphoma (PCNSL) . Secondary ocular lymphomas associated with systemic findings, however, are classically found to have choroidal infiltration (rather than vitreoretinal) due to hematogenous spread [2, 3].
The existence of SVRL is of clinical significance as it can masquerade as PVRL/PCNSL along with other vitreoretinal diseases. In cases of PVRL, the central nervous system is involved in 50–80% of patients, and therefore, the diagnostic focus is primarily intraocular and intracranial [1, 7]. In recent studies, SVRL associated with systemic lymphoma was found in 5–28% of patients after diagnostic vitrectomy [1, 3, 8]. Therefore, the lower prevalence of SRVL can often mislead clinicians into suspecting retinitis or vasculitis in the setting of immunosuppression from systemic lymphoma and chemotherapy, resulting in a delay of appropriate diagnosis and treatment [4, 6]. Among these reports, only a single other case was identified where ocular manifestations were the presenting signs of an undiagnosed systemic DLBCL. As such, in patients with recurrent vitreous hemorrhage without a clear etiology, as in our case, clinical suspicion for PVRL and SVRL may be warranted.
Intraocular lymphoma is diagnosed histologically with immunohistochemistry, flow cytometry, and PCR analysis . Typically, intraocular lymphoma is of the non-germinal center B cell, or activated B cell (ABC), subtype . Immunoprofiling usually demonstrates positive CD20, PAX5, CD79, BCL6, and BCL2, and an absence of CD10 and other plasma cell markers [2, 3, 5]. Our patient was classified by his oncologist as the ABC phenotype and analysis demonstrated positive CD19 and CD20, as well as negative CD10 on flow cytometry. IGH gene rearrangement analysis was positive, which is typical for vitreoretinal DLBCL [3, 8]. Karakawa et al. have suggested that the high correlation between SVRL and systemic ABC DLBCL may indicate a specific tropism for intraocular tissues .
The treatment for VRL is not well studied. In general, ABC DLBCL subtype has a poorer prognosis compared to germinal center B cell-like subtype (GCB) . Current treatment for systemic ABC DLBCL is R-CHOP, although evidence has shown relapse in 40% of patients thereby spurring on newer frontline treatments targeting B cell pathways such as bortezomib or pomalidomide [9, 10]. For vitreoretinal DLBCL, there is no universally accepted treatment. Typical methods include a combination of local, regional, or systemic approaches. In prior published case reports, all patients received local therapy of either intravitreal methotrexate, rituximab, or both. Most patients also received local whole-brain and/or ocular radiation therapy, and only some underwent systemic chemotherapy plus intrathecal methotrexate. Our patient was treated with intravitreal injections of rituximab and methotrexate combined with systemic therapy with intrathecal methotrexate and R-CHOP.
Prognosis of PVRL has shown 3-year overall survival rates of 75–86% with treatment [8, 11]. The paucity of literature makes establishing prognosis for SVRL very difficult. Of the 9 patients included in 4 different case studies, 4 patients demonstrated overall survival time ranging from 14 to 62 months, while the remaining 55% were presently alive at the time of writing although the length of survival was unreportable due to lack of documentation [3,4,5,6].
Although VRL is rare, ocular involvement preceding systemic involvement is even rarer. As seen in our case, recurrent vitreous hemorrhage without a clear underlying etiology may warrant some clinical suspicion for VRL. Its association with systemic lymphoma necessitates thorough and rapid intraocular, CNS, and systemic evaluation in patients. Treatment of VRL is not well established due to a lack of evidence-based studies for this uncommon condition. A combination of local, regional, and systemic therapies along with careful lifelong surveillance is recommended.
Availability of data and materials
Activated B cell subtype
Central nervous system
Diffuse large B cell lymphoma
Germinal center B cell-like subtype
Optical coherence tomography
Primary CNS lymphoma
Rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone
Mochizuki M, Singh AD (2009) Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm 17(2):69–72
Araujo I, Coupland SE (2017) Primary vitreoretinal lymphoma -- a review. Asia Pac J Ophthalmol (Phila) 6(3):283–289
Salomao DR, Pulido JS, Johnston PB, Canal-Fontcuberta I, Feldman AL (2013) Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma. JAMA Ophthalmol 131(9):1151–1158
Ryan ME, Shantha JG, Grossniklaus HE, Yeh S (2015) Secondary vitreoretinal lymphoma masquerading as acute retinal necrosis. Ophthalmic Surg Lasers Imaging Retina 46(10):1048–1050
Echegaray JJ, Llop S, Sepulveda M, Velez-Rosario R, Perez N, Oliver AL (2018) Intravitreal rituximab for the treatment of a secondary intraocular relapse of a large B-cell lymphoma. Am J Ophthalmol Case Rep 9:77–79
Say EA, Knupp CL, Gertsch KR, Chavala SH (2012) Metastatic B-cell lymphoma masquerading as infectious retinitis and vasculitis. Oncol Lett 3(6):1245–1248
Peterson K, Gordon KB, Heinemann MH, DeAngelis LM (1993) The clinical spectrum of ocular lymphoma. Cancer 72(3):843–849
Karakawa A, Taoka K, Kaburaki T, Tanaka R, Shinozaki-Ushiku A, Hayashi H, Miyagi-Maeshima A, Nishimura Y, Uekusa T, Kojima Y, Fukayama M, Kurokawa M, Aihara M (2018) Clinical features and outcomes of secondary intraocular lymphoma. Br J Haematol 183(4):668–671. https://doi.org/10.1111/bjh.15005. Epub 2017 Nov 16. PubMed PMID: 29143310
Nowakowski GS, Czuczman MS (2015) ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection? Am Soc Clin Oncol Educ Book:e449–e457. https://doi.org/10.14694/EdBook_AM.2015.35.e449
Sehn LH (2012) Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2012:402–409
Lee S, Kim MJ, Kim JS, Oh SY, Kim SJ, H Kwon Y, Chung IY, Kang JH, Yang DH, Kang HJ, H Yoon D, Kim WS, Kim HJ, Suh C (2015) Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Res 50(4):242–247
This manuscript was presented at the Atlantic Coast Retina Club/Macula 2019. Boston, MA, January 10, 2019.
Klorfine Foundation (to TAA). http://www.klorfinefoundation.org/. None of the authors have any financial disclosures or any proprietary interests in the material described within the article.
Ethics approval and consent to participate
Consent for publication
Consent to publish the case report has been obtained from the patient and does not disclose the identity of the patient.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Fan, K.C., Tran, K.D., Harbour, J.W. et al. Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma. J Ophthal Inflamm Infect 9, 11 (2019). https://doi.org/10.1186/s12348-019-0177-8